Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Lung and Upper Aerodigestive Cancer Research Group

Publications

View All  |  2013-2010  |  2009-2005

2013

  • Coming soon

2012

  • Coming soon

2011

  • Doria-Rose VP and Szabo E. Lung Cancer Screening and Prevention of Lung Cancer. In: Current Multidisciplinary Oncology: Lung Cancer. Edited by K Kernstine and K Reckamp. NY, NY: Demos Medical, 2011, pp 53-72.
  • Kelly RJ, Lopez-Chavez A, Szabo E. Criteria of evidence to move potential chemopreventive agents into late phase clinical trials. Current Drug Targets. 2010 Dec 15. [Epub ahead of print].
    [ PubMed Abstract ]
  • Giaccone G, Rajan A, Berman A, Kelly R, Szabo E, Lopez-Chavez A, Trepel J, Lee M-J, Cao L, Espinoza-Delgado I, Spittler J, Loehrer P. Belinostat Phase II Study in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol, In Press.
  • Meyskens FL, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, Kelloff GJ, Khleif SN, Sigman CC, Szabo E. Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res, In Press.
  • Reid JM, Walden C, Qin R, Ziegler KLA, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Mandrekar SJ, Ames MM, Limburg PJ. Single-dose Phase 0 exploratory pharmacokinetic clinical trial comparing five oral formulations of SR13668, an orally active AKT pathway inhibitor. Cancer Prev Res, In Press.
  • Veronesi G, Szabo E, DeCensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Ferretti S, Pelosi G, Lazzeroni M, Serrano D, Lippman SM, Spaggiari L, Nardi-Pantoli A, Harari S, Varricchio C, Bonanni B. Randomized Phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res. 2011 Jan;4(1):34-42. Epub 2010 Dec 16.
    [ PubMed Abstract ]

2010

  • Demaria S, Pikarsky E, Karin M, Coussens LM, Chen Y-C, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, et al. Cancer and inflammation: promise for biological therapy. J Immunother. 2010 May;33(4):335-51.
    [ PubMed Abstract ]
  • Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, Cooper K, Walker D, McWilliams A, Liu G, Szabo E, Brody J, Massion PP, Lenburg ME, Lam S, Bild AH, Spira A. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med. 2010 Apr 7;2(26):26ra25.
    [ PubMed Abstract ]
  • Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, Varricchio MC, Veronesi G, Radice D, Feroce I, Nardi-Pantoli A, Lippman SM, Szabo E, Bonnanni B. Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology. Contemp Clin Trials. 2010 Nov;31(6):612-9. Epub 2010 Aug 16.
    [ PubMed Abstract ]
  • Maley CC, Szabo E, Reid BJ. Somatic Evolution in Neoplastic Progression and Cancer Prevention. In: Advances in Understanding the Basic Pathogenesis and Clinical Management of Pre-invasive Disease. Edited by R. Fitzgerald. NY, NY: Springer, 2010, pp 111-128.
  • Sharon E, Kelly RJ, Szabo E. Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. Head Neck Oncol. 2010 May 26;2:12
    [ PubMed Abstract ]
  • Smith, JJ, Dunn, B, Greenwald, P (2010). Dynamics of Cancer Prevention. In C H Yarbro, M Frogge, M Goodman, and S Groenwald (Eds.), Cancer Nursing: Principles and Practices (7th Edition). Sudbury, MA: Jones & Bartlett Publishers.
  • Szabo E. Assessing efficacy in early-phase cancer prevention trials: the case of the Ki-67 proliferation index in lung cancer prevention. Cancer Prev Res 2010 Feb;3(2):128-31. Epub 2010 Jan 26.
    [ PubMed Abstract ]
  • Szabo E. Phase II cancer prevention clinical trials. Semin Oncol. 2010 Aug;37(4):359-66. Review.
    [ PubMed Abstract ]
  • Wang Y, James M, Wen W, Lu Y, Szabo E, Lubet RA, You M. Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. Mol Cancer Ther. 2010 Nov;9(11):3074-82. Epub 2010 Nov 2.
    [ PubMed Abstract ]

2009

  • Doria-Rose VP, Marcus PM, Szabo E, Tockman MS, Prorok PC. Randomized controlled trials of the efficacy of lung cancer screening by sputum cytology revisited: a combined mortality analysis from the Johns Hopkins Lung Project and the Memorial Sloan-Kettering Lung Study. Cancer. 2009 Nov 1;115(21):5007-17.
    [ PubMed Abstract ]
  • Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett SM. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J Natl Cancer Inst. 2009 Apr 15;101(8):554-9. Epub 2009 Apr 7.
    [ PubMed Abstract ]

2008

  • Chen J, Lam S, Pilon A, McWilliams A, MacAulay C, Szabo E. Higher levels of the anti-inflammatory protein CC10 are associated with improvement in bronchial dysplasia and sputum cytometric assessment in individuals at high risk for lung cancer. Clin Cancer Res. 2008 Mar 1;14(5):1590-7.
    [ PubMed Abstract ]
  • Girnun GD, Howe LR, Manne S, Mao JT, Reid ME, Szabo E. Meeting report: sixth annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res. 2008 Jul;1(2):146-9.
    [ PubMed Abstract ]
  • Lubet RA, Szabo E, Christov K, Bode AM, Ericson ME, Steele VE, Juliana MM, Grubbs CJ. Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes. Mol Cancer Ther. 2008 Apr;7(4):972-9. Epub 2008 Mar 28.
    [ PubMed Abstract ]
  • Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green E, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ. Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):674-9.
    [ PubMed Abstract ]
  • Smith JJ, Berg CD. Lung Cancer Screening: Promise and Practice. Seminars in Oncology Nursing. 2008 24:9-15.
  • Szabo E. Assessing efficacy in early-phase cancer prevention trials: the case of oral premalignancy. Cancer Prev Res. 2008 Oct;1(5):312-5.
    [ PubMed Abstract ]
  • Szabo, E. First do no harm: when is it appropriate to plan a cancer prevention clinical trial? Nature Clin Practice Oncol, 5:348-356, 2008.
  • Chen J, Lam S, Pilon A, McWilliams A, Melby J, Szabo E. The association between the anti-inflammatory protein CC10 and smoking status among participants in a chemoprevention trial. Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):577-83.
    [ PubMed Abstract ]

2007

  • Kelloff GJ, Sullivan DC, Baker H, et al. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007;3(1):1-33.
    [ PubMed Abstract ]
  • Rhoden J, Mao JT, Szabo E, Kelley M, Kurie J, Bepler G. Lung cancer chemoprevention – an ACCP evidence-based clinical practice guideline. Chest. 2007 Sep;132(3 Suppl):56S-68S.
    [ PubMed Abstract ]
  • Szabo E. Proliferative changes in chemoprevention trials: learning from secondary endpoints. J Natl Cancer Inst. 2007 Nov 7;99(21):1565-7. Epub 2007 Oct 30.
    [ PubMed Abstract ]

2006

  • Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia (IEN) and cancer (AACR Cancer Prevention Task Force). Clin Cancer Res. 2006 Jun 15;12(12):3661-97.
    [ PubMed Abstract ]
  • Lam S, McWilliams A, leRiche J, MacAulay C, Wattenberg L, Szabo E. A Phase I study of myo-inositol for lung cancer chemoprevention. Cancer Epidemiol Biomarkers Prev, 2006 Aug;15(8):1526-31.
    [ PubMed Abstract ]
  • Szabo E. Selecting targets for cancer prevention: where do we go from here? Nat Rev Cancer. 2006 Nov;6(11):867-74. Epub 2006 Oct 12.
    [ PubMed Abstract ]

2005

  • Grem JL, Morrison G, Guo X-D, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH. A Phase I and pharmacologic study of 17-(Allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol. 2005 Mar 20;23(9):1885-93.
    [ PubMed Abstract ]
  • Meyskens FL and Szabo E. Diet and cancer: the disconnect between epidemiology and randomized clinical trials. Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1366-9.
    [ PubMed Abstract ]
  • Meyskens FL, Szabo E. How should we move the field of chemopreventive agent development forward in a productive manner? Recent Results Cancer Res. 2005;166:113-24.
    [ PubMed Abstract ]
  • Wright M, Morrison G, Lin PX, Leonard G, Nguyen D, Guo XD, Szabo E, Hopkins J, Leguizamo J, Harold N, Fioravanti S, Schuler B, Monahan BP, Saif MW, Quinn MG, Pang J, Grem JL. A Phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors. Clin Cancer Res. 2005 Jun 1;11(11):4144-50.
    [ PubMed Abstract ]
  • Szabo E. Multiagent Chemoprevention - Clinical Concepts. ASCO 2005 Education Book, pgs. 135-137, 2005.
  • Szabo E. New Targets for Aerodigestive Cancer Prevention: Where Do We Go from Here? Cancer Prevention, Fall 2005, Issue #6, http://www.nypcancerprevention.org/ Exit Disclaimer .

Back to top